Compare SYSCO Corporation (SYY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? SYSCO Corporation trades at $83.86 (market cap $40.32B), while Vertex Pharmaceuticals Incorporated trades at $528.88 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× SYSCO Corporation's market cap, and SYSCO Corporation pays a 2.61% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SYY | VRTX | |
|---|---|---|
Market Cap | $40.32B | $134.25B |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $529.65 |
52-Week Low | $69.30 | $376.62 |
Enterprise Value | $53.50B | $128.37B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYY trades at $83.87, down 0.5% for the day, with a neutral technical signal and bullish moving averages. The company reported Q4 2026 EPS of $1.53, beating estimates, and revenue of $81.37B in 2025, with steady growth. Analyst consensus is a Buy with a $88.25 price target, and recent news highlights strong quarterly results and efficiency initiatives.
Outlook is positive due to earnings beats and growth initiatives, but risks include margin pressure and debt levels. The stock offers value with a P/E of 23.02 and P/S of 0.48, supported by institutional optimism, though macroeconomic uncertainty remains a concern.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
